Everything below concerns Mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
He then participated in the mixed doubles match with Siegemund, against Australia's Storm Hunter and Matthew Ebden. Saving two match points, Zverev and Siegemund won their match in a match tiebreak score of 15–13, and with Kerber's earlier narrow win against Alja Tomljanovic, Team Germany qualified for the final against Team Poland. After Kerber was unsuccessful against the Polish world No. 1, Iga Swiatek, Zverev made a critical comeback win against Poland's Hubert Hurkacz, saving two championship points in the process and levelled the tie 1–1. Partnering once more with Siegemund, Zverev played the mixed doubles match and successfully defeated the Polish pair of Hurkacz and Swiatek in a decisive match tiebreak and won the United Cup for Team Germany. In the process, he won his first team event since the Laver Cup in 2021. In 2025, Zverev won his opening round-robin matches against Thiago Monteiro and Zhang Zhizhen but withdrew from his next match due to a bicep strain injury. Team Germany then failed to progress to the quarterfinals, failing to defend their title. In 2026, Zverev defeated Tallon Griekspoor in straight sets and won the mixed doubles match alongside Laura Siegemund to secure the tie over Netherlands. In their next tie against Poland, Zverev lost in straight sets to Hubert Hurkacz, who was making a return from a seven-month hiatus due to injury.
Le Cake-Walk infernal, sold in the United States as The Cake Walk Infernal and in Britain as The Infernal Cake Walk, is a 1903 French silent trick film by Georges Méliès. It was sold by Méliès's Star Film Company and is numbered 453–457 in its catalogues. The film features the cakewalk, which was booming in popularity in 1903. Méliès appears in the film as Pluto/Satan and as the grotesque dancing demon. This rhythm-dependent film was probably filmed to piano accompaniment in the studio. Special effects in the film were worked with trapdoors, stage machinery, pyrotechnics, substitution splices, and multiple exposures. The Infernal Cake Walk features several examples of elements reused from, or later reused in, other films also made by Méliès. The demon masks in the film were originally made for Méliès's A Trip to the Moon (1902), where they are worn by the Selenites (Moon dwellers); similarly, the effect of dancing limbs had previously been used in Dislocation Extraordinary (1901). Conversely, Méliès reused The Infernal Cakewalk's grotto set in his later film The Damnation of Faust (1903), and recycled the will-o'-the-wisp effect in The Infernal Cauldron (1903).
The prostate's changes of shape, which facilitate the mechanical switch between urination and ejaculation, are mainly driven by the two longitudinal muscle systems running along the prostatic urethra. These are the urethral dilator (musculus dilatator urethrae) on the urethra's front side, which contracts during urination and thereby shortens and tilts the prostate in its vertical dimension thus widening the prostatic section of the urethral tube, and the muscle switching the urethra into the ejaculatory state (musculus ejaculatorius) on its backside. In case of an operation, e.g. because of benign prostatic hyperplasia (BPH), damaging or sparing of these two muscle systems varies considerably depending on the choice of operation type and details of the procedure of the chosen technique. The effects on postoperational urination and ejaculation vary correspondingly.
Sources: en.wikipedia.org
He concluded that perineurial cysts should be considered in patients with gradually worsening sacral nerve symptoms when imaging or surgery fails to reveal a herniated disc. In 1953, Dr. Isadore Tarlov published a monograph titled Sacral Nerve-Root Cysts: Another Cause of the Sciatic or Cauda Equina Syndrome, which compiled his anatomical, histological, and clinical research on perineurial cysts. The book combined scientific analysis with case studies to illustrate the symptoms, surgical techniques, and outcomes associated with sacral cysts. In Chapter 8, titled "Clinical Significance", Tarlov presented ten patient case reports documented between 1948 and 1952, four of which involved surgeries he personally performed. The remaining cases were managed by other surgeons using various techniques. Reported symptoms included pain, paresthesia, numbness (e.g., of the penis, thigh, buttocks, rectum, or vagina), urinary incontinence, and foot weakness with absent ankle reflex. Complete surgical removal of isolated cysts often led to full recovery, while patients with multiple cysts saw more limited improvement due to conservative surgical approaches. He concluded the monograph by urging increased clinical awareness of these lesions, stating that perineurial cysts may be a surgically treatable cause of sciatic and sacrococcygeal syndromes.
=== Supporting === Xu Di as Xue Zhenzhu (薛珍珠), Luo Zijun and Luo Ziqun's mother. Zhang Lingxin as Luo Ziqun (罗子群), Luo Zijun's younger sister. Zheng Luoqian as Wei Wei'an (薇薇安) Wang Tianze as Leng Jiaqing (冷佳清), Ling Ling's son and Chen Junsheng's stepson. Vivian Wu as Aunt Wu Luan Yuanhui as Bai Guang Chuo Ni as Luoluo Mei Ting as Zhuo Jianqing's former girlfriend Tan Kai as Adom Kong Wei as a single woman Zhang Yanyan as Su Manshu Hou Yansong as Laojin Wei Zhihao as Ping'er Song Yunhao as Duan Xiaotian Xu Caigen as Cui Baojian Ren Jimin as Chen Junsheng's father Zhang Lan as Chen Junsheng's mother Ru Tian as Ya Qin Min Tianhao as A Hui Shi An as Lawyer Li Guo Tongtong as Xiaodong Chen Guanning as Cui Baojian's son Yang Mei as a chubby girl. Sun Yuhan as Caicai Xu Sheng as Phil Guan Xueying as Sandra Dong Bi Hanwen as the lawyer of Chen Junsheng Qu Lingzi as He Han's assistant Lu Ling as Yingying Cheng Hong as the marketing manager Huang Jing as Tang Jing's assistant Yu Mingjia as the CEO of Angel Ren Donglin as Li Rui Zhang Yi as Luo Ping
Sac6 Sla1p Srv2 (CAP) S-adenosyl-L-homocysteine hydrolase, (SAHH) Sla2p Synaptopodin Scinderin (adseverin) Synapsins Scruin Spectrin Severin Spectraplakins SVSII Shot (Short stop) Spire Shroom Smitin (Smooth Musc.Titin) Supervillin SipA Smoothelin Sucrose synthetase SipC Sra-1 Spinophilin Ssk2p Swinholide Talin protein Toxophilin Twinfilin Tau Trabeculin Twinstar TCP-1 Transgelin Transgelin 2 Transgelin 3 Tensin Tropomodulin Thymosin Tropomyosin Titin Troponin TOR2 Tubulin bIV Ulapualide Utrophin Unc-87 Unc-60 (ADF/cofilins) VASP Vav Verprolin VDAC Vibrio cholerae RTX toxin Villin Vinculin Vitamin D-binding protein WIP WASp Y-box proteins YpkA (YopO) Zipper protein Zo-1 Zyxin The Encyclopaedia of Actin-Binding Proteins (and Drugs)– alphabetical list, sourced profile for each Maciver, Sutherland (ed.). "The Encyclopaedia of Actin-Binding Proteins (and Drugs)". Maciver Lab Web Page (online ed.). School of Biomedical Sciences, University of Edinburgh. Archived from the original on 2005-11-24. Actin-Binding+Proteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.